— **Suspension of a marketing authorization (Article 18 of Regulation (EEC) No 2309/93)**

Date of the decision	Name of the medicinal product	Holder of the marketing authorization	Number of the entry in the Community Register	Date of notification
14.1.2004	Tasmar	Roche Registration Ltd 40 Broadwater Road Welwyn Garden City Hertfordshire AL7 3AY United Kingdom	EU/1/97/044	16.1.2004

— **Modification of a marketing authorization (Article 34 of Regulation (EEC) No 2309/93): Accepted**

Date of the decision	Name of the medicinal product	Holder of the marketing authorization	Number of the entry in the Community Register	Date of notification
9.1.2004	Nobilis OR inac	Intervet International BV Wim de Körverstraat 35 5831 AN Boxmeer Nederland	EU/2/02/036/001-002	13.1.2004

Anyone wishing to consult the public assessment report on the medicinal products in question and the decisions relating thereto is invited to contact:

The European Agency for the Evaluation of Medicinal Products
7 Westferry Circus
Canary Wharf
London E14 4HB
United Kingdom

Non-opposition to a notified concentration

(Case COMP/M.3362 — RBS/BSCH/Britax)

(2004/C 44/04)

(Text with EEA relevance)

On 4 February 2004, the Commission decided not to oppose the above notified concentration and to declare it compatible with the common market. This decision is based on Article 6(1)(b) of Council Regulation (EEC) No 4064/89. The full text of the decision is only available in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

— as a paper version through the sales offices of the Office for Official Publications of the European Communities (see list on the last page),

— in electronic form in the 'CEN' version of the CELEX database, under document No 304M3362. CELEX is the computerised documentation system of European Community law.

For more information concerning subscriptions please contact:

EUR-OP,
Information, Marketing and Public Relations,
2, rue Mercier,
L-2985 Luxembourg.
Tel. (352) 29 29 427 18, fax (352) 29 29 427 09.
